134 related articles for article (PubMed ID: 21106711)
1. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
Sissung TM; Danesi R; Kirkland CT; Baum CE; Ockers SB; Stein EV; Venzon D; Price DK; Figg WD
J Clin Endocrinol Metab; 2011 Feb; 96(2):E368-72. PubMed ID: 21106711
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
Pastina I; Giovannetti E; Chioni A; Sissung TM; Crea F; Orlandini C; Price DK; Cianci C; Figg WD; Ricci S; Danesi R
BMC Cancer; 2010 Sep; 10():511. PubMed ID: 20875115
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel treatment in castration-resistant prostate cancer: the triad gene-drug-disease.
Faucz FR
J Clin Endocrinol Metab; 2011 Feb; 96(2):351-3. PubMed ID: 21296995
[No Abstract] [Full Text] [Related]
6. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
[TBL] [Abstract][Full Text] [Related]
7. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
Narita S; Tsuchiya N; Yuasa T; Maita S; Obara T; Numakura K; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Int J Clin Oncol; 2012 Jun; 17(3):204-11. PubMed ID: 21706123
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.
Jeske S; Tagawa ST; Olowokure O; Selzer J; Giannakakou P; Nanus DM
Urol Oncol; 2011; 29(6):676-81. PubMed ID: 20451413
[TBL] [Abstract][Full Text] [Related]
9. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Sissung TM; Baum CE; Deeken J; Price DK; Aragon-Ching J; Steinberg SM; Dahut W; Sparreboom A; Figg WD
Clin Cancer Res; 2008 Jul; 14(14):4543-9. PubMed ID: 18628469
[TBL] [Abstract][Full Text] [Related]
10. A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.
Hu Z; Song CG; Lu JS; Luo JM; Shen ZZ; Huang W; Shao ZM
J Cancer Res Clin Oncol; 2007 Dec; 133(12):969-78. PubMed ID: 17562079
[TBL] [Abstract][Full Text] [Related]
11. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
12. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Fizazi K
Ann Oncol; 2009 Apr; 20(4):703-8. PubMed ID: 19179557
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
Italiano A; Ortholan C; Oudard S; Pouessel D; Gravis G; Beuzeboc P; Bompas E; Fléchon A; Joly F; Ferrero JM; Fizazi K
Eur Urol; 2009 Jun; 55(6):1368-75. PubMed ID: 18706755
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
[TBL] [Abstract][Full Text] [Related]
15. Castrate-resistant prostate cancer: postdocetaxel management.
Zhao S; Yu EY
Curr Opin Urol; 2013 May; 23(3):201-7. PubMed ID: 23344012
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
[TBL] [Abstract][Full Text] [Related]
17. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.
Hahn NM; Zon RT; Yu M; Ademuyiwa FO; Jones T; Dugan W; Whalen C; Shanmugam R; Skaar T; Sweeney CJ
Ann Oncol; 2009 Dec; 20(12):1971-6. PubMed ID: 19605506
[TBL] [Abstract][Full Text] [Related]
19. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
20. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
